• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert Review of Molecular Diagnostics >Multiplex ligation-dependent probe amplification for HER2 testing in breast cancer.
【24h】

Multiplex ligation-dependent probe amplification for HER2 testing in breast cancer.

机译：用于乳腺癌HER2检测的多重连接依赖探针扩增。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The amplification of the human EGF receptor 2 (HER2) gene is the underlying mechanism for HER2 overexpression in breast cancer. HER2 positivity is an adverse prognostic factor, but these patients benefit from targeted therapy with humanized monocolonal antibodies to HER2 in both the metastatic and adjuvant settings.The American Society of Clinical Oncology's Tumour Marker Guidelines Panel and the College of American Pathologists recommend routine testing of HER2 on all newly diagnosed and metastatic invasive breast cancers [1]. The choice of assays has included immuno-histochemistry (IHC) for the detection of protein overexpression and in situ hybridization (ISH) to ascertain gene amplification. Concordance between the results reported by local laboratories and central testing can be suboptimal, ranging from 74 to 81.6% for IHC and 67 to 88.1% for fluorescence ISH. The discordances include false-positive and false-negative results.
机译：人类EGF受体2（HER2）基因的扩增是HER2在乳腺癌中过度表达的潜在机制。 HER2阳性是不利的预后因素，但这些患者在转移性和佐剂性治疗中均受益于人源化针对HER2的人源单克隆抗体的靶向治疗。对所有新诊断和转移性浸润性乳腺癌的影响[1]。检测方法的选择包括用于检测蛋白过表达的免疫组织化学（IHC）和用于确定基因扩增的原位杂交（ISH）。本地实验室报告的结果与中心测试之间的一致性可能不是最佳的，IHC范围从74％到81.6％，荧光ISH范围从67％到88.1％。不一致之处包括假阳性和假阴性结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号